Arion Group Generics is an integral part of organization. In the recent past, Our Generic
has been associated with several first-launch products in generic that have contributed
significantly to the company’s growth. With a product portfolio consisting around 200 distributors and many more in the pipeline. Arion Generic is earmarked to achieve
greater milestones in the near future. The Government of India is marking it mandatory
for the Physicians to prescribe the generics.
Our Generics business in India has contributed excellent for the domestic
pharmaceutical revenues with 1,500+ partners covering the entire country.
The business operates within an extremely competitive environment in a highly fragmented market with 43000+ pharmaceutical players. Despite competitive pressures and on- going regulatory challenges, the business delivered strong growth in the year under review and continued its leadership position in the market. Our focus lies in strengthening our position in Tier 3 and Tier 4 towns along with expanding the product portfolio to cater to the needs of our patients. The Generics business continues to operate in a challenging regulatory environment with uncertain policies governing trade margins, branded generics, DPCO and product approvals.
